CN105177091A - 用于纯化双特异性抗体的抗体修饰方法 - Google Patents

用于纯化双特异性抗体的抗体修饰方法 Download PDF

Info

Publication number
CN105177091A
CN105177091A CN201510498322.8A CN201510498322A CN105177091A CN 105177091 A CN105177091 A CN 105177091A CN 201510498322 A CN201510498322 A CN 201510498322A CN 105177091 A CN105177091 A CN 105177091A
Authority
CN
China
Prior art keywords
antibody
polypeptide
amino
variable region
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510498322.8A
Other languages
English (en)
Chinese (zh)
Inventor
井川智之
角田浩行
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority claimed from CNA2007800201263A external-priority patent/CN101460622A/zh
Publication of CN105177091A publication Critical patent/CN105177091A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201510498322.8A 2006-03-31 2007-03-30 用于纯化双特异性抗体的抗体修饰方法 Pending CN105177091A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2006097795 2006-03-31
JP2006-097795 2006-03-31
JP2006275804 2006-10-06
JP2006-275804 2006-10-06
CNA2007800201263A CN101460622A (zh) 2006-03-31 2007-03-30 用于纯化双特异性抗体的抗体修饰方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800201263A Division CN101460622A (zh) 2006-03-31 2007-03-30 用于纯化双特异性抗体的抗体修饰方法

Publications (1)

Publication Number Publication Date
CN105177091A true CN105177091A (zh) 2015-12-23

Family

ID=38563592

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510498322.8A Pending CN105177091A (zh) 2006-03-31 2007-03-30 用于纯化双特异性抗体的抗体修饰方法

Country Status (8)

Country Link
US (2) US9670269B2 (fr)
EP (3) EP4218801A3 (fr)
JP (3) JP5144499B2 (fr)
CN (1) CN105177091A (fr)
DK (1) DK2009101T3 (fr)
ES (1) ES2654040T3 (fr)
HK (1) HK1217217A1 (fr)
WO (1) WO2007114325A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111479829A (zh) * 2017-11-01 2020-07-31 中外制药株式会社 具有降低的生物活性的抗体变体和同种型

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
WO2005035754A1 (fr) * 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Anticorps a double specificite de substitution de proteine fonctionnelle
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2006106905A1 (fr) * 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Procede pour la production de polypeptide au moyen de la regulation d’un ensemble
JP4917024B2 (ja) * 2005-04-08 2012-04-18 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能代替抗体
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
WO2009000099A2 (fr) 2007-06-25 2008-12-31 Esbatech Ag Méthodes de modification d'anticorps et anticorps modifiés présentant des propriétés fonctionnelles améliorées
EP3127921A1 (fr) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
TWI418363B (zh) * 2007-09-28 2013-12-11 Chugai Pharmaceutical Co Ltd 血漿中動態經改善之磷脂醯肌醇蛋白聚醣３抗體
KR101643005B1 (ko) * 2007-12-05 2016-07-28 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
ES2774337T3 (es) * 2008-01-07 2020-07-20 Amgen Inc Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
NZ623716A (en) 2008-04-11 2016-04-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2409990A4 (fr) 2009-03-19 2013-01-23 Chugai Pharmaceutical Co Ltd Variant d'une région constante d'anticorps
BRPI1011145A2 (pt) 2009-05-15 2016-03-15 Chugai Pharmaceutical Co Ltd anticorpo anti-axl
KR102010827B1 (ko) 2009-06-26 2019-08-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
CA2785414C (fr) * 2009-12-25 2019-01-22 Tomoyuki Igawa Procede de modification de polypeptide pour purifier un multimere de polypeptide
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
JP5104996B2 (ja) 2010-01-29 2012-12-19 東レ株式会社 ポリ乳酸系樹脂シート
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
EP3029066B1 (fr) 2010-07-29 2019-02-20 Xencor, Inc. Anticorps à points isoélectriques modifiés
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
CA2819356C (fr) 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Molecule de liaison a l'antigene, apte a se lier de facon repetee a une pluralite de molecules d'antigene
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
EP3604330A1 (fr) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Anticorps fc spécifique au fcgammariib
EP2500073A1 (fr) 2011-03-17 2012-09-19 ChromaCon AG Procédé pour l'identification et la purification de polypeptides plurispécifiques
TWI687439B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
WO2013022855A1 (fr) * 2011-08-05 2013-02-14 Xencor, Inc. Anticorps avec points isoélectriques modifiés et immunofiltration
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP6310394B2 (ja) * 2011-10-10 2018-04-11 ゼンコア インコーポレイテッド 抗体を精製する方法
KR102168733B1 (ko) * 2011-10-31 2020-10-23 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
CN109897103B (zh) 2011-11-04 2024-05-17 酵活英属哥伦比亚有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
KR20140100532A (ko) * 2011-11-30 2014-08-14 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
EP2862875B1 (fr) 2012-06-14 2023-09-06 Chugai Seiyaku Kabushiki Kaisha MOLÉCULE DE LIAISON À L'ANTIGÈNE CONTENANT UNE RÉGION Fc MODIFIÉE
WO2014004586A1 (fr) 2012-06-25 2014-01-03 Zymeworks Inc. Processus et procédés pour la fabrication efficace d'anticorps asymétriques hautement purs dans des cellules de mammifère
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
CA2889951C (fr) 2012-11-02 2023-04-18 Zymeworks Inc. Structures cristallines de domaines fc heterodimeres
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
MX2015006758A (es) 2012-11-28 2016-06-10 Zymeworks Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados geneticamente y usos de estos.
CN105102618B (zh) * 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
WO2014145907A1 (fr) 2013-03-15 2014-09-18 Xencor, Inc. Ciblage des lymphocytes t avec des protéines hétérodimères
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
ES2885696T3 (es) * 2013-03-15 2021-12-15 Xencor Inc Proteínas heterodiméricas
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
JP6598680B2 (ja) 2013-04-02 2019-10-30 中外製薬株式会社 Ｆｃ領域改変体
BR112016006197B1 (pt) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha Método para produzir um anticorpo biespecífico de polipeptídeos
CA2922950A1 (fr) 2013-09-30 2015-04-02 Shinya Ishii Procede de production d'une molecule de liaison a l'antigene dans lequel on utilise un phage auxiliaire modifie
TWI712421B (zh) 2013-11-11 2020-12-11 日商中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
JP6817064B2 (ja) 2013-11-27 2021-01-20 ザイムワークス，インコーポレイテッド Ｈｅｒ２を標的とする二重特異性抗原結合性コンストラクト
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
PE20170071A1 (es) 2014-03-14 2017-03-17 Novartis Ag Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
AP2016009475A0 (en) 2014-03-28 2016-09-30 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
US11306156B2 (en) 2014-05-28 2022-04-19 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
WO2016014553A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Récepteurs d'antigènes chimères synthétisés par l'intermédiaire d'une sortase
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
AU2015292755B2 (en) 2014-07-21 2020-11-12 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
EP4205749A1 (fr) 2014-07-31 2023-07-05 Novartis AG Cellules contenant un récepteur d'antigène chimérique optimisé en sous-ensemble
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
MX2017003645A (es) 2014-09-17 2017-05-30 Novartis Ag Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
JP2017536830A (ja) 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体
EP3928788A1 (fr) 2014-11-26 2021-12-29 Xencor, Inc. Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
WO2016090034A2 (fr) 2014-12-03 2016-06-09 Novartis Ag Méthodes de pré-conditionnement de cellules b dans une thérapie car
KR20180054923A (ko) 2014-12-19 2018-05-24 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
KR20170110129A (ko) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
TW202339800A (zh) 2015-02-27 2023-10-16 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
WO2016141387A1 (fr) 2015-03-05 2016-09-09 Xencor, Inc. Modulation de lymphocytes t avec des anticorps bispécifiques et des hybrides fc
WO2016159213A1 (fr) 2015-04-01 2016-10-06 中外製薬株式会社 Procédé pour la production d'un hétéro-oligomère polypeptidique
HRP20220893T1 (hr) 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
JP6962819B2 (ja) * 2015-04-10 2021-11-05 アディマブ， エルエルシー 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
EP3286211A1 (fr) 2015-04-23 2018-02-28 Novartis AG Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
WO2016173605A1 (fr) 2015-04-29 2016-11-03 Institute For Research In Biomedicine Neutralisation ultra-puissante de cytokines par des anticorps multispécifiques et utilisations associées
MA56416A (fr) * 2015-05-12 2022-05-04 Regeneron Pharma Détermination de la pureté de protéines multimériques
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3316902A1 (fr) 2015-07-29 2018-05-09 Novartis AG Polythérapies comprenant des molécules d'anticorps contre tim -3
WO2017019894A1 (fr) 2015-07-29 2017-02-02 Novartis Ag Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3
RU2018116846A (ru) 2015-10-08 2019-11-08 Займворкс Инк. Антигенсвязывающие полипептидные конструкции, содержащие легкие цепи каппа и лямбда, и их применения
JP6925278B2 (ja) 2015-11-18 2021-08-25 中外製薬株式会社 液性免疫応答の増強方法
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
EP3387013B1 (fr) 2015-12-07 2022-06-08 Xencor, Inc. Anticorps hétérodimères se liant à cd3 et psma
KR20180094977A (ko) 2015-12-17 2018-08-24 노파르티스 아게 c-Met 억제제와 PD-1에 대한 항체 분자의 조합물 및 그의 용도
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
KR20180118175A (ko) 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
CA3016424A1 (fr) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Medicament therapeutique induisant des lesions cellulaires a utiliser dans le traitement du cancer
WO2017165683A1 (fr) 2016-03-23 2017-09-28 Novartis Ag Mini-corps sécrétés par des cellules et leurs usages
SG11201809041TA (en) 2016-04-15 2018-11-29 Novartis Ag Compositions and methods for selective protein expression
WO2017210617A2 (fr) 2016-06-02 2017-12-07 Porter, David, L. Régimes thérapeutiques pour cellules exprimant un récepteur antigénique chimérique (car)
MA45255A (fr) 2016-06-14 2019-04-17 Xencor Inc Anticorps inhibiteurs de points de contrôle bispécifiques
EP3475304B1 (fr) 2016-06-28 2022-03-23 Xencor, Inc. Anticorps hétérodimériques qui se lient au récepteur 2 de la somatostatine
JP7219376B2 (ja) 2016-07-15 2023-02-08 ノバルティス アーゲー キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
CN110214150A (zh) 2016-07-28 2019-09-06 诺华股份有限公司 嵌合抗原受体和pd-1抑制剂的组合疗法
WO2018026819A2 (fr) 2016-08-01 2018-02-08 Novartis Ag Traitement du cancer au moyen d'un récepteur d'antigène chimérique en combinaison avec un inhibiteur d'une molécule de macrophage pro-m2
CA3026050A1 (fr) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liees a il-8
WO2018038469A1 (fr) * 2016-08-20 2018-03-01 (주)아이벤트러스 Procédé de confirmation de production sélective d'anticorps bispécifique souhaité
KR101933656B1 (ko) * 2016-08-20 2018-12-28 (주) 아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
IL265144B1 (en) 2016-09-06 2024-06-01 Chugai Pharmaceutical Co Ltd Methods for using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
AU2017341047A1 (en) 2016-10-07 2019-05-02 Novartis Ag Chimeric antigen receptors for the treatment of cancer
US10550185B2 (en) 2016-10-14 2020-02-04 Xencor, Inc. Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
WO2018160731A1 (fr) 2017-02-28 2018-09-07 Novartis Ag Compositions d'inhibiteur shp et utilisations pour une thérapie de récepteur d'antigène chimère
JP7039175B2 (ja) 2017-03-07 2022-03-22 モレックス エルエルシー コネクタ
EP3615068A1 (fr) 2017-04-28 2020-03-04 Novartis AG Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
WO2018201056A1 (fr) 2017-04-28 2018-11-01 Novartis Ag Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
KR20240056666A (ko) 2017-06-05 2024-04-30 얀센 바이오테크 인코포레이티드 이중특이성 항체 생성을 위한 표면 전하 조작 방법
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
KR20200022447A (ko) 2017-06-27 2020-03-03 노파르티스 아게 항-tim-3 항체의 투여 요법 및 그의 용도
WO2019006472A1 (fr) 2017-06-30 2019-01-03 Xencor, Inc. Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
SG10201913147WA (en) 2017-07-11 2020-02-27 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
EP3655023A1 (fr) 2017-07-20 2020-05-27 Novartis AG Régimes posologiques pour des anticorps anti-lag3 et leurs utilisations
JP2020533016A (ja) * 2017-08-01 2020-11-19 エービー ストゥーディオ インコーポレイテッド 二重特異性抗体およびその使用
PE20210005A1 (es) 2017-09-29 2021-01-05 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
MX2020003497A (es) 2017-10-20 2020-07-22 Hoffmann La Roche Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
CA3078676A1 (fr) 2017-10-30 2019-05-09 F. Hoffmann-La Roche Ag Procede de generation in vivo d'anticorps multispecifiques a partir d'anticorps monospecifiques
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3706793A1 (fr) 2017-11-08 2020-09-16 Xencor, Inc. Anticorps bispécifiques et monospécifiques utilisant de nouvelles séquences anti-pd-1
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
EP3732195A4 (fr) 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha Agent thérapeutique induisant une cytotoxicité
WO2019152660A1 (fr) 2018-01-31 2019-08-08 Novartis Ag Polythérapie utilisant un récepteur antigénique chimérique
EP3765494A4 (fr) 2018-03-15 2022-03-23 Chugai Seiyaku Kabushiki Kaisha Anticorps dirigés contre le virus de la dengue présentant une réactivité croisée au virus zika et procédés d'utilisation
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
JP2021520829A (ja) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
KR20210010862A (ko) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
WO2019210153A1 (fr) 2018-04-27 2019-10-31 Novartis Ag Thérapies reposant sur des cellules car-t présentant une efficacité améliorée
WO2019226658A1 (fr) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions multispécifiques de liaison à l'antigène et procédés d'utilisation
TW202003580A (zh) 2018-05-21 2020-01-16 美商坎伯斯治療有限責任公司 用於增強nk細胞對標靶細胞之殺死之組合物及方法
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2019276578A1 (en) 2018-06-01 2021-01-14 Compugen Ltd Anti-PVRIG/anti-TIGIT bispecific antibodies and methods of use
JP7438988B2 (ja) 2018-06-13 2024-02-27 ノバルティス アーゲー Ｂｃｍａキメラ抗原受容体及びその使用
JP7472119B2 (ja) 2018-06-19 2024-04-22 アターガ，エルエルシー 補体第５成分に対する抗体分子およびその使用
US20210261669A1 (en) 2018-06-20 2021-08-26 Chugai Seiyaku Kabushiki Kaisha Method for activating immune response of target cell and composition therefor
WO2019243626A1 (fr) 2018-06-22 2019-12-26 Genmab A/S Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (fr) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Procédé de traitement de tumeurs neuroendocrines
MX2021003765A (es) 2018-10-03 2021-07-15 Xencor Inc Proteínas il-12 de fusión a fc heterodimérico.
KR20210107628A (ko) 2018-11-13 2021-09-01 콤파스 테라퓨틱스 엘엘씨 체크포인트 분자에 대한 다중특이적 결합 작제물 및 이의 용도
KR20210106491A (ko) 2018-12-20 2021-08-30 노파르티스 아게 약제학적 조합물
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
SG11202106393SA (en) 2018-12-24 2021-07-29 Sanofi Sa Pseudofab-based multispecific binding proteins
EP3924054A1 (fr) 2019-02-15 2021-12-22 Novartis AG Dérivés de 3-(1-oxo-5-(pipéridin-4-yl)isoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
JP7488826B2 (ja) 2019-02-15 2024-05-22 ノバルティス アーゲー 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US20220088075A1 (en) 2019-02-22 2022-03-24 The Trustees Of The University Of Pennsylvania Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
US11472890B2 (en) 2019-03-01 2022-10-18 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
AU2020253833A1 (en) 2019-03-29 2021-10-28 Atarga, Llc Anti FGF23 antibody
KR20220005568A (ko) * 2019-05-09 2022-01-13 제넨테크, 인크. 항체의 제조 방법
US20210054049A1 (en) * 2019-05-09 2021-02-25 Merus N.V. Variant domains for multimerizing proteins and separation thereof
TW202112808A (zh) 2019-06-05 2021-04-01 日商中外製藥股份有限公司 抗體切斷部位結合分子
KR20220033493A (ko) 2019-07-10 2022-03-16 추가이 세이야쿠 가부시키가이샤 클로딘 6 결합 분자 및 그의 사용
MX2022004769A (es) 2019-10-21 2022-05-16 Novartis Ag Inhibidores de tim-3 y sus usos.
WO2021079188A1 (fr) 2019-10-21 2021-04-29 Novartis Ag Polythérapies comprenant du vénétoclax et des inhibiteurs de tim-3
KR20220105664A (ko) 2019-11-26 2022-07-27 노파르티스 아게 Bcma 및 cd19에 결합하는 키메라 항원 수용체 및 이의 용도
BR112022011998A2 (pt) 2019-12-20 2022-08-30 Novartis Ag Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
BR112022011723A2 (pt) 2019-12-27 2022-09-06 Chugai Pharmaceutical Co Ltd Anticorpo anti-ctla-4 e uso do mesmo
JP2023510393A (ja) 2020-01-17 2023-03-13 ノバルティス アーゲー 骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ
US20210222244A1 (en) 2020-01-17 2021-07-22 Becton, Dickinson And Company Methods and compositions for single cell secretomics
CA3173737A1 (fr) 2020-02-27 2021-09-02 Novartis Ag Procedes de production de cellules exprimant un recepteur antigenique chimerique
US20230121511A1 (en) 2020-03-31 2023-04-20 Chugai Seiyaku Kabushiki Kaisha Method for producing multispecific antigen-binding molecules
EP4130732A4 (fr) * 2020-04-02 2024-06-19 Chugai Seiyaku Kabushiki Kaisha Procédé d'analyse de molécules d'impuretés dans une composition contenant des molécules de liaison à un antigène multi-spécifiques
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US20230321067A1 (en) 2020-06-23 2023-10-12 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2020162622A (ja) * 2020-06-25 2020-10-08 インスティテュート フォー リサーチ イン バイオメディシン 多重特異性抗体によるサイトカインの非常に強力な中和およびその利用
EP4182025A1 (fr) 2020-07-16 2023-05-24 Novartis AG Anticorps anti-bêtacelluline, fragments de ceux-ci et molécules de liaison multi-spécifiques
WO2022026592A2 (fr) 2020-07-28 2022-02-03 Celltas Bio, Inc. Molécules d'anticorps contre le coronavirus et leurs utilisations
WO2022025220A1 (fr) 2020-07-31 2022-02-03 中外製薬株式会社 Composition pharmaceutique comprenant des cellules exprimant un récepteur chimérique
WO2022029573A1 (fr) 2020-08-03 2022-02-10 Novartis Ag Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione substitués par hétéroaryle et leurs utilisations
CA3192204A1 (fr) 2020-08-19 2022-02-24 Xencor, Inc. Anticorps anti-cd28 et/ou compositions anti-b7h3
JPWO2022044248A1 (fr) 2020-08-28 2022-03-03
WO2022043557A1 (fr) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Méthode de traitement de cancers exprimant le psma
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4240765A2 (fr) 2020-11-06 2023-09-13 Novartis AG Variants fc d'anticorps
WO2022104061A1 (fr) 2020-11-13 2022-05-19 Novartis Ag Polythérapies avec des cellules exprimant un récepteur antigénique chimérique (car)
EP4284510A1 (fr) 2021-01-29 2023-12-06 Novartis AG Régimes posologiques d'anticorps anti-cd73 et anti-entpd2 et leurs utilisations
IL305736A (en) 2021-03-09 2023-11-01 Xencor Inc Heterodimeric antibodies that bind CD3 and CLDN6
WO2022192586A1 (fr) 2021-03-10 2022-09-15 Xencor, Inc. Anticorps hétérodimères qui se lient au cd3 et au gpc3
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
MX2023014453A (es) 2021-06-25 2024-01-31 Chugai Seiyaku Kk Uso de anticuerpos anti-antigeno 4 del linfocito t citotoxico (anti-ctla-4).
AR126220A1 (es) 2021-06-25 2023-09-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-ctla-4
WO2023044483A2 (fr) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement du cancer positif her2
WO2023053282A1 (fr) 2021-09-29 2023-04-06 中外製薬株式会社 Agent thérapeutique induisant la cytotoxicité destiné à être utilisé dans le traitement du cancer
AR127269A1 (es) 2021-10-08 2024-01-03 Chugai Pharmaceutical Co Ltd Formulación de anticuerpo anti-hla-dq2.5
WO2023092004A1 (fr) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions et méthodes pour le traitement de troubles liés à tau
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2023220695A2 (fr) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement du cancer her2 positif
WO2024030976A2 (fr) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions et procédés permettant le franchissement de la barrière hémato-encéphalique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005537009A (ja) * 2002-08-29 2005-12-08 スノル・モレキュラー・コーポレーション 免疫系分子をヒト化する方法
CN101198698A (zh) * 2005-03-31 2008-06-11 中外制药株式会社 通过调节缔合制备多肽的方法

Family Cites Families (350)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE370449B (fr) 1970-08-29 1974-10-14 Philips Nv
JPS5334319B2 (fr) 1971-12-28 1978-09-20
JPS5717624B2 (fr) 1974-04-17 1982-04-12
JPS59878B2 (ja) 1975-09-04 1984-01-09 松下電工株式会社 感知器
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH0234615Y2 (fr) 1986-08-08 1990-09-18
JPH06104071B2 (ja) 1986-08-24 1994-12-21 財団法人化学及血清療法研究所 第▲ｉｘ▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5126250A (en) 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
IL89491A0 (en) 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH0341033A (ja) 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
KR100236375B1 (ko) 1989-12-11 1999-12-15 오트리브 데이비스 더블유 진단제 또는 치료제를 목표부위에 타게팅하기 위한 제제 및 키트
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
TW212184B (fr) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH05184383A (ja) 1990-06-19 1993-07-27 Dainabotsuto Kk 二重特異性抗体
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH05199894A (ja) 1990-08-20 1993-08-10 Takeda Chem Ind Ltd 二重特異性抗体および抗体含有薬剤
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
JPH05304992A (ja) 1991-06-20 1993-11-19 Takeda Chem Ind Ltd ハイブリッド・モノクローナル抗体および抗体含有薬剤
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
CA2119930C (fr) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production d'anticorps chimeres - demarche combinatoire
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JPH05203652A (ja) 1992-01-28 1993-08-10 Fuji Photo Film Co Ltd 抗体酵素免疫分析法
JPH05213775A (ja) 1992-02-05 1993-08-24 Otsuka Pharmaceut Co Ltd Ｂｆａ抗体
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
CA2131151A1 (fr) 1992-03-24 1994-09-30 Kevin S. Johnson Methodes de production d'elements formant des paires specifiques de liaison
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
CA2126967A1 (fr) * 1992-11-04 1994-05-11 Anna M. Wu Nouvelle construction d'anticorps
CA2150262C (fr) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Proteines fixatrices multivalentes et multispecifiques, fabrication et utilisation
JP3312357B2 (ja) 1992-12-11 2002-08-05 ザ ダウ ケミカル カンパニー 多価の一本鎖抗体
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
AU7214294A (en) 1993-07-01 1995-01-24 Dade International Inc. Process for the preparation of factor x depleted plasma
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
US6214613B1 (en) 1993-12-03 2001-04-10 Ashai Kasei Kogyo Kabushiki Kaisha Expression screening vector
DE122009000068I2 (de) * 1994-06-03 2011-06-16 Ascenion Gmbh Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
MX9700312A (es) 1994-07-11 1997-07-31 Univ Texas Metodos y composiciones para la coagulacion especifica en vasculatura.
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
WO1996004925A1 (fr) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugues et anticorps de type humain specifiques contre des lymphomes malins a cellules b et des cellules leucemiques
US6451523B1 (en) * 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
RU2147443C1 (ru) 1994-10-07 2000-04-20 Чугаи Сейяку Кабусики Кайся Лечебные средства против хронического ревматоидного артрита, содержащие антагонист il-6 в качестве эффективного компонента
RU2147442C1 (ru) * 1994-10-21 2000-04-20 Кисимото Тадамицу Фармацевтическая композиция для профилактики или лечения заболеваний, вызываемых образованием il-6
WO1996016673A1 (fr) 1994-12-02 1996-06-06 Chiron Corporation Methode permettant d'induire une reponse immunitaire avec un anticorps bispecifique
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
AU4865296A (en) 1995-02-28 1996-09-18 Procter & Gamble Company, The Preparation of noncarbonated beverage products having superior microbial stability
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0822830B1 (fr) 1995-04-27 2008-04-02 Amgen Fremont Inc. Anticorps anti-IL-8 dérivés de xenosouris immunisées
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69636015T2 (de) 1995-05-03 2007-01-04 Bioenhancementsments Ltd. Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird
US6018032A (en) 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
US20020193571A1 (en) 1996-01-08 2002-12-19 Paul J. Carter Wsx receptor agonist antibodies
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
FR2745008A1 (fr) 1996-02-20 1997-08-22 Ass Pour Le Dev De La Rech En Recepteur nucleaire de glucocorticoides modifie, fragments d'adn codant pour ledit recepteur et procedes dans lesquels ils sont mis en oeuvre
US5945231A (en) * 1996-03-26 1999-08-31 California Institute Of Technology Direct liquid-feed fuel cell with membrane electrolyte and manufacturing thereof
JP3032287U (ja) 1996-06-10 1996-12-17 幸喜 高橋 人 形
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
ZA976326B (en) 1996-07-19 1998-02-03 Amgen Inc Analogs of cationic proteins.
IL129164A (en) 1996-09-26 2007-05-15 Chugai Pharmaceutical Co Ltd An antibody against peptides associated with human parathyroid hormone
JPH10165184A (ja) 1996-12-16 1998-06-23 Tosoh Corp 抗体、遺伝子及びキメラ抗体の製法
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US6323000B2 (en) * 1996-12-20 2001-11-27 Clark A. Briggs Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof
US7541034B1 (en) 1997-03-20 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
WO1999002567A2 (fr) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions et procedes destines a des homoconjugues d'anticorps qui induisent l'arret de la croissance ou l'apoptose de cellules tumorales
US5980893A (en) 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999018212A1 (fr) * 1997-10-03 1999-04-15 Chugai Seiyaku Kabushiki Kaisha Anticorps humain naturel
ES2299241T3 (es) 1998-03-17 2008-05-16 Chugai Seiyaku Kabushiki Kaisha Preventivos o remedios para enfermedades intestinales inflamatorias que contienen anticuerpos antagonistas del receptor il-6.
CN1303431A (zh) 1998-04-03 2001-07-11 中外制药株式会社 抗人组织因子和人源化抗体以及人源化抗体的制作方法
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7081360B2 (en) * 1998-07-28 2006-07-25 Cadus Technologies, Inc. Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
US20020142374A1 (en) * 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
WO2000018806A1 (fr) 1998-09-25 2000-04-06 Horst Lindhofer Anticorps bispecifiques et trispecifiques reagissant de façon specifique avec des antigenes d'enveloppe pouvant etre induits, en tant que structures cibles operationnelles
AU764211C (en) 1998-12-01 2006-03-30 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
US7286585B2 (en) * 1998-12-21 2007-10-23 Finisar Corporation Low temperature grown layers with migration enhanced epitaxy adjacent to an InGaAsN(Sb) based active region
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
AR030019A1 (es) 1999-05-18 2003-08-13 Smithkline Beecham Corp Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
CA2390662A1 (fr) 1999-12-14 2001-06-21 The Burnham Institute Polypeptides bcl-g, acides nucleique de codage et leurs procedes d'utilisation
WO2001064713A2 (fr) 2000-03-01 2001-09-07 Christoph Gasche Variants du recepteur d'interleukine-10 (il-10) des mammiferes
TWI241345B (en) 2000-03-10 2005-10-11 Chugai Pharmaceutical Co Ltd Apoptosis inducing polypeptide
ATE382055T1 (de) 2000-03-22 2008-01-15 Curagen Corp Wnt-1 verwandte polypeptide und dafür kodierende nukleinsäuren
EP1283722A1 (fr) 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Utilisation combinee d'anticorps ou d'antagonistes anti-cytokine et d'anti-cd20 pour le traitement du lymphome b
WO2001075454A2 (fr) * 2000-04-03 2001-10-11 Oxford Glycosciences (Uk) Ltd. Molecules d'acides nucleiques, polypeptides et leurs utilisations pour diagnostic et le traitement de la maladie d'alzheimer notamment
AU2001246934A1 (en) 2000-04-17 2001-10-30 Chugai Seiyaku Kabushiki Kaisha Agonist antibodies
EP1278512A2 (fr) 2000-05-03 2003-01-29 MBT Munich Biotechnology AG Agents de diagnostic cationique, d'imagerie et de therapie associes a des sites vasculaires actives
WO2001090192A2 (fr) 2000-05-24 2001-11-29 Imclone Systems Incorporated Proteines bispecifiques de liaison a l'antigene du type immunoglobulines, et procede de production correspondant
JP2004512262A (ja) 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
SG136804A1 (en) 2000-07-12 2007-11-29 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
EP1304573A4 (fr) 2000-07-17 2006-06-07 Chugai Pharmaceutical Co Ltd Methode de criblage d'un ligand dote d'une activite biologique
CN1592645A (zh) 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
EP1327680B1 (fr) 2000-10-20 2008-04-02 Chugai Seiyaku Kabushiki Kaisha Anticorps modifie, agoniste de tpo
KR100870123B1 (ko) * 2000-10-20 2008-11-25 츄가이 세이야꾸 가부시키가이샤 저분자화 아고니스트 항체
ATE391174T1 (de) * 2000-10-20 2008-04-15 Chugai Pharmaceutical Co Ltd Modifizierter tpo-agonisten antikörper
CA2424371A1 (fr) 2000-10-20 2003-04-01 Chugai Seiyaku Kabushiki Kaisha Fragments d'anticorps monoclonal agoniste
WO2002036165A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
DE60143544D1 (de) * 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US7148321B2 (en) 2001-03-07 2006-12-12 Emd Lexigen Research Center Corp. Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002078612A2 (fr) 2001-04-02 2002-10-10 Euro-Celtique S.A. Anticorps synthetique contenant de la thrombopoietine (tpo) pour la stimulation de la production de plaquettes
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
UA83791C2 (ru) * 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
EP1780273B1 (fr) * 2001-06-22 2010-10-06 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de prolifération de cellules contenant un anticorps anti-glypican 3
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
JP2005507659A (ja) * 2001-10-15 2005-03-24 イミューノメディクス、インコーポレイテッド 直接ターゲッティング結合タンパク質
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
CA2472922A1 (fr) * 2002-02-11 2003-08-21 Genentech, Inc. Variantes d'anticorps a vitesses d'association d'antigene accelerees
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
AU2003227504A1 (en) 2002-04-15 2003-10-27 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
DE60327199D1 (de) 2002-04-26 2009-05-28 Chugai Pharmaceutical Co Ltd Verfahren zum screening auf agonistische antikörper
JP2004086862A (ja) 2002-05-31 2004-03-18 Celestar Lexico-Sciences Inc タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
EP1510943A4 (fr) * 2002-05-31 2007-05-09 Celestar Lexico Sciences Inc Dispositif de prediction d'interactions
WO2003104425A2 (fr) 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nouveaux anticorps anti-cd22 stables
US20060141456A1 (en) 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
EP1539947A4 (fr) 2002-08-15 2006-09-06 Epitomics Inc Anticorps humanises de lapin
WO2004019966A1 (fr) 2002-08-27 2004-03-11 Chugai Seiyaku Kabushiki Kaisha Methode de stabilisation de preparations de solution de proteines
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
AU2003271175A1 (en) * 2002-10-11 2004-05-04 Masahiro Abe Cell death-inducing agent
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB0224082D0 (en) * 2002-10-16 2002-11-27 Celltech R&D Ltd Biological products
NZ568769A (en) 2002-10-17 2010-04-30 Genmab As Human monoclonal antibodies against CD20
SI2263692T1 (sl) 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
WO2004060919A1 (fr) 2002-12-26 2004-07-22 Chugai Seiyaku Kabushiki Kaisha Anticorps agoniste dirigé contre un hétérorécepteur
WO2004065611A1 (fr) 2003-01-21 2004-08-05 Chugai Seiyaku Kabushiki Kaisha Procede de selection par criblage d'une chaine legere d'anticorps
EP1608684A2 (fr) 2003-02-07 2005-12-28 Protein Design Labs, Inc. Anticorps anti-amphireguline (ar) et leur utilisation dans le traitement du cancer et du psoriasis
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2004081048A1 (fr) 2003-03-13 2004-09-23 Chugai Seiyaku Kabushiki Kaisha Ligand a activite agoniste vis-a-vis d'un recepteur ayant subi une mutation
JP2004279086A (ja) * 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
JPWO2004087763A1 (ja) * 2003-03-31 2006-07-27 中外製薬株式会社 Ｃｄ２２に対する改変抗体およびその利用
GB2400851B (en) 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP2395016A3 (fr) * 2003-05-30 2012-12-19 Merus B.V. Conception et utilisation de régions variables appariées de molécules de liaison spécifiques
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
US8597911B2 (en) * 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
EP1636264A2 (fr) 2003-06-24 2006-03-22 MERCK PATENT GmbH Molecules de recepteur du facteur de necrose tumorale a immunogenicite reduite
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
JP2005101105A (ja) 2003-09-22 2005-04-14 Canon Inc 位置決め装置、露光装置、デバイス製造方法
JP2005112514A (ja) 2003-10-06 2005-04-28 Tadano Ltd 伸縮ブーム
WO2005035754A1 (fr) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Anticorps a double specificite de substitution de proteine fonctionnelle
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
WO2005063815A2 (fr) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Variants de polypeptides de liaison au recepteur fc$g(g) et procede apparentes
US20050142133A1 (en) * 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
WO2005058815A2 (fr) * 2003-12-10 2005-06-30 Medarex, Inc. Anticorps ip-10 et leurs utilisations
SI2418220T1 (sl) 2003-12-10 2017-10-30 E. R. Squibb & Sons, L.L.C. Interferon alfa protitelesa in njihova uporaba
US20070281327A1 (en) * 2003-12-12 2007-12-06 Kiyotaka Nakano Methods of Screening for Modified Antibodies With Agonistic Activities
JPWO2005056605A1 (ja) * 2003-12-12 2007-12-06 中外製薬株式会社 ３量体以上の受容体を認識する改変抗体
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
WO2005062916A2 (fr) 2003-12-22 2005-07-14 Centocor, Inc. Methodes permettant de generer des molecules multimeres
DK1707627T3 (da) 2003-12-25 2012-12-17 Kyowa Hakko Kirin Co Ltd Antagonistisk anti-CD40-antistofmutant.
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
CN1330448C (zh) * 2004-02-25 2007-08-08 苏州宝时得电动工具有限公司 往复式电动工具的往复杆平衡机构
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
CA2561264A1 (fr) 2004-03-24 2005-10-06 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
WO2005112564A2 (fr) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Régions variables d'anticorps humanisés et lignée germinale et méthodes de fabrication et d'utilisation
TW200605906A (en) 2004-05-11 2006-02-16 Chugai Pharmaceutical Co Ltd Remedy for thrombopenia
EA010350B1 (ru) 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Ｔａｇ-72에 대한 인간화 항체
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20060019342A1 (en) * 2004-06-25 2006-01-26 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
DE102004032634A1 (de) 2004-07-06 2006-02-16 Sms Demag Ag Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk
ES2353967T3 (es) 2004-07-09 2011-03-08 Chugai Seiyaku Kabushiki Kaisha Anticuerpo anti-glipicano 3 .
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
CN101001873B (zh) 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Fc区变体
WO2006028936A2 (fr) * 2004-09-02 2006-03-16 Genentech, Inc. Molecules heteromultimeriques
MX2007002883A (es) 2004-09-13 2007-06-15 Macrogenics Inc Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.
WO2006031994A2 (fr) 2004-09-14 2006-03-23 Xencor, Inc. Domaines fc monomeres des immunoglobulines
EP1799718A1 (fr) 2004-09-14 2007-06-27 National Institute for Biological Standards and Control (NIBSC) Vaccin
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
WO2006047350A2 (fr) 2004-10-21 2006-05-04 Xencor, Inc. Variants d'immunoglobuline igg a fonction effectrice optimisee
EA012162B1 (ru) 2004-10-22 2009-08-28 Эмджен Инк. Способ рефолдинга рекомбинантных антител
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
CA2586803C (fr) 2004-12-14 2012-12-11 Ge Healthcare Bio-Sciences Ab Purification d'immunoglobulines
EP2208783A1 (fr) * 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Procédé de préparation d'un anticorps à l'aide d'une cellule dont la fonction de transporteur du fucose est inhibée
US8728828B2 (en) 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
PT2476705E (pt) 2004-12-28 2016-02-09 Innate Pharma Anticorpos monoclonais contra nkg2a
EP1847602B1 (fr) 2005-01-12 2014-04-23 Kyowa Hakko Kirin Co., Ltd. ANTICORPS IgG2 HUMAINS STABILISÉS
AU2006204791A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc Antibodies and Fc fusion proteins with altered immunogenicity
CA2602663A1 (fr) 2005-03-31 2006-10-05 Xencor, Inc. Variants fc presentant des proprietes optimisees
EP1870458B1 (fr) 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha ISOMERES STRUCTURELS sc(Fv)2
JP4917024B2 (ja) * 2005-04-08 2012-04-18 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能代替抗体
ES2446923T3 (es) 2005-04-15 2014-03-10 Genentech, Inc. Variantes de cadena beta de HGF
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
CA2607281C (fr) 2005-05-05 2023-10-03 Duke University Traitements des maladies auto-immunes par anticorps anti-cd19
EP1908482B1 (fr) * 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilisant pour une préparation de protéine contenant de la méglumine et son utilisation
CN101262885B (zh) * 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
EP1900814A4 (fr) 2005-06-10 2010-07-21 Chugai Pharmaceutical Co Ltd MUTANT DIRIGÉ SUR LE SITE sc(Fv)2
EP1893647A2 (fr) * 2005-06-23 2008-03-05 MedImmune, Inc. Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises
US20070036786A1 (en) 2005-07-11 2007-02-15 Nadine Tuaillon Method of treating autoimmune disease using humanized anti-CD16A antibodies
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
WO2007024535A2 (fr) 2005-08-19 2007-03-01 Wyeth Anticorps antagonistes contre gdf-8 et utilisations pour le traitement de als et d'autres troubles associes a gdf-8
US20070134234A1 (en) 2005-09-29 2007-06-14 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
WO2007060411A1 (fr) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anticorps anti-tnf alpha qui inhibent sélectivement le signal tnf alpha par le p55r
EP1820513A1 (fr) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction des cellules tumorales exprimant à un niveau bas ou moyen des antigènes cibles associés aux tumeurs, par des anticorps trifonctionels bispécifiques
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
EP2006380A4 (fr) 2006-03-23 2010-08-11 Kyowa Hakko Kirin Co Ltd Anticorps agoniste dirige contre le recepteur de la thrombopoietine humaine
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
DK2006381T3 (en) * 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
WO2007116962A1 (fr) 2006-04-07 2007-10-18 Osaka University Promoteur de régénération musculaire
NZ573132A (en) 2006-06-06 2012-05-25 Glaxo Group Ltd Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
PL2047863T3 (pl) * 2006-06-08 2014-01-31 Chugai Pharmaceutical Co Ltd Zapobieganie lub leczenie chorób zapalnych
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
WO2008090960A1 (fr) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. Composition d'anticorps génétiquement recombinés capable de se lier spécifiquement au ganglioside gm2
WO2008092117A2 (fr) 2007-01-25 2008-07-31 Xencor, Inc. Nouvelles insertions, délétions et substitutions d'immunoglobulines
WO2008119353A1 (fr) 2007-03-29 2008-10-09 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
US20100291023A1 (en) 2007-05-31 2010-11-18 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
EP2666787B1 (fr) 2007-05-31 2022-02-09 Genmab A/S ANTICORPS IgG4 STABLES
CA2691618A1 (fr) 2007-06-29 2009-01-08 Schering Corporation Utilisation de mdl-1
EP2031064A1 (fr) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Procédé d'augmentation de titres de protéines
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
EP3127921A1 (fr) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
WO2009041734A1 (fr) 2007-09-26 2009-04-02 Kyowa Hakko Kirin Co., Ltd. Anticorps agoniste anti-récepteur de la thrombopoïétine humaine
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
AU2008304756B8 (en) 2007-09-26 2015-02-12 Chugai Seiyaku Kabushiki Kaisha Anti-IL-6 receptor antibody
TWI418363B (zh) 2007-09-28 2013-12-11 Chugai Pharmaceutical Co Ltd 血漿中動態經改善之磷脂醯肌醇蛋白聚醣３抗體
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009053368A1 (fr) 2007-10-22 2009-04-30 Merck Serono S.A. Ifn-bêta unique fusionné à un fragment fc d'igg muté
KR101643005B1 (ko) 2007-12-05 2016-07-28 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP5568478B2 (ja) 2007-12-18 2014-08-06 バイオアライアンス セー．フェー． 癌細胞で発現するｃｄ−４３およびｃｅａの炭水化物含有エピトープを認識する抗体およびそれを使用する方法
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
ES2774337T3 (es) 2008-01-07 2020-07-20 Amgen Inc Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
EP2250279B1 (fr) 2008-02-08 2016-04-13 MedImmune, LLC Anticorps anti-ifnar1 ayant une affinité réduite pour le ligand fc
PT2274008E (pt) 2008-03-27 2014-05-12 Zymogenetics Inc Composições e métodos para inibição de pdgfrbeta e vegf-a
NZ623716A (en) 2008-04-11 2016-04-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2722600C (fr) 2008-05-01 2014-01-21 Amgen Inc. Anticorps anti-hepcidine et methodes d'utilisation associees
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
RU2011116112A (ru) 2008-09-26 2012-11-10 Роше Гликарт Аг (Ch) Биспецифические анти-egfr/анти-igf-1r антитела
AR074438A1 (es) 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
WO2010064090A1 (fr) 2008-12-02 2010-06-10 Pierre Fabre Medicament Procédé de modulation de l'activité antagoniste d'un anticorps monoclonal
DE202008016028U1 (de) 2008-12-04 2010-04-15 Melitta Haushaltsprodukte Gmbh & Co. Kg Behälter zur Aufbewahrung von Gegenständen
BRPI1006998A2 (pt) 2009-01-23 2015-08-25 Biogen Idec Inc Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
AR075798A1 (es) 2009-03-05 2011-04-27 Abbott Lab Proteinas de union a il-17 (interleuquina 17)
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2409990A4 (fr) 2009-03-19 2013-01-23 Chugai Pharmaceutical Co Ltd Variant d'une région constante d'anticorps
US9228017B2 (en) * 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2233500A1 (fr) 2009-03-20 2010-09-29 LFB Biotechnologies Variantes Fc optimisées
KR20120057565A (ko) 2009-04-01 2012-06-05 제넨테크, 인크. 항-ＦｃＲＨ５ 항체 및 면역접합체 및 사용 방법
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
CA2759233C (fr) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Procede de fabrication de molecules heteromultimeres
KR102010827B1 (ko) 2009-06-26 2019-08-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
CA2785414C (fr) 2009-12-25 2019-01-22 Tomoyuki Igawa Procede de modification de polypeptide pour purifier un multimere de polypeptide
RS55229B1 (sr) 2009-12-29 2017-02-28 Emergent Product Dev Seattle Heterodimerni vezujući proteini i njihove upotrebe
JP5947727B2 (ja) 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
CA2787783A1 (fr) 2010-01-20 2011-07-28 Tolerx, Inc. Anticorps anti-ilt5 et fragments d'anticorps se liant a ilt5
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
JP5820800B2 (ja) 2010-03-02 2015-11-24 協和発酵キリン株式会社 改変抗体組成物
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
PE20130393A1 (es) 2010-03-11 2013-04-07 Rinat Neuroscience Corp Anticuerpos con union de antigenos dependiente de ph
US9162161B2 (en) 2010-03-31 2015-10-20 Jsr Corporation Filler for affinity chromatography
KR102152109B1 (ko) 2010-04-20 2020-09-07 젠맵 에이/에스 이종이량체 항체 ｆｃ-함유 단백질 및 그의 생산 방법
RU2624027C2 (ru) 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN114805583A (zh) 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
EP3029066B1 (fr) 2010-07-29 2019-02-20 Xencor, Inc. Anticorps à points isoélectriques modifiés
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
EP2699263A4 (fr) 2011-04-20 2014-12-24 Liquidating Trust Procédés pour réduire une réponse immunitaire indésirable à un antigène étranger chez un sujet humain avec des anticorps anti-cd4 ou des fragments de ceux-ci se liant aux cd4 ou des molécules se liant aux cd4
WO2013060867A2 (fr) 2011-10-27 2013-05-02 Genmab A/S Production de protéines hétérodimères
KR102168733B1 (ko) 2011-10-31 2020-10-23 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
CN109897103B (zh) 2011-11-04 2024-05-17 酵活英属哥伦比亚有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
CA2860543C (fr) 2012-03-08 2018-04-24 F. Hoffmann-La Roche Ag Formulation d'anticorps anti-peptide abeta
US9815909B2 (en) 2012-03-13 2017-11-14 Novimmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
WO2013147153A1 (fr) 2012-03-29 2013-10-03 株式会社未来創薬研究所 Anticorps anti-lamp5 et son utilisation
NZ630551A (en) 2012-04-20 2017-11-24 Merus Nv Methods and means for the production of ig-like molecules
WO2014028354A1 (fr) 2012-08-13 2014-02-20 Regeneron Pharmaceuticals, Inc. Anticorps anti-pcsk9 ayant des caractéristiques de liaison dépendantes du ph
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
CA2889951C (fr) 2012-11-02 2023-04-18 Zymeworks Inc. Structures cristallines de domaines fc heterodimeres
AU2014233528B2 (en) 2013-03-15 2019-02-28 Abbvie Biotherapeutics Inc. Fc variants
BR112016006197B1 (pt) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha Método para produzir um anticorpo biespecífico de polipeptídeos
CN110627907B (zh) 2013-11-04 2024-03-29 艾科诺斯科技股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
TW201625299A (zh) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
JP6630036B2 (ja) 2014-09-30 2020-01-15 Jsr株式会社 標的物の精製方法、及び、ミックスモード用担体
KR20170110129A (ko) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2016159213A1 (fr) 2015-04-01 2016-10-06 中外製薬株式会社 Procédé pour la production d'un hétéro-oligomère polypeptidique
MX2017010734A (es) 2015-04-17 2017-12-04 Hoffmann La Roche Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
JP2018123055A (ja) 2015-04-24 2018-08-09 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
TW202402326A (zh) 2016-04-28 2024-01-16 日商中外製藥股份有限公司 含抗體製劑
TW201836636A (zh) 2017-03-31 2018-10-16 公立大學法人奈良縣立醫科大學 含有替代凝血因子ｖｉｉｉ功能之多特異性抗原結合分子之用於預防和／或治療凝血因子ｉｘ異常症的醫藥組合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005537009A (ja) * 2002-08-29 2005-12-08 スノル・モレキュラー・コーポレーション 免疫系分子をヒト化する方法
CN101198698A (zh) * 2005-03-31 2008-06-11 中外制药株式会社 通过调节缔合制备多肽的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.MARGARET MERCHANT等: "An efficient route to human bispecific IgG", 《NATURE BIOTECHNOLOGY》 *
OLIVER MANZKE等: "Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography", 《JOURNAL OF IMMUNOLOGICAL METHODS》 *
PAUL CARTER: "Bispecific human IgG by design", 《JOURNAL OF IMMUNOLOGICAL METHODS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111479829A (zh) * 2017-11-01 2020-07-31 中外制药株式会社 具有降低的生物活性的抗体变体和同种型

Also Published As

Publication number Publication date
JP6219877B2 (ja) 2017-10-25
US10934344B2 (en) 2021-03-02
US9670269B2 (en) 2017-06-06
EP3345616A1 (fr) 2018-07-11
US20090263392A1 (en) 2009-10-22
EP2009101A4 (fr) 2009-10-21
US20170283483A1 (en) 2017-10-05
ES2654040T3 (es) 2018-02-12
HK1217217A1 (zh) 2016-12-30
EP4218801A3 (fr) 2023-08-23
JP6055271B2 (ja) 2016-12-27
EP2009101A1 (fr) 2008-12-31
WO2007114325A1 (fr) 2007-10-11
EP2009101B1 (fr) 2017-10-25
JP2015146822A (ja) 2015-08-20
JP2013078313A (ja) 2013-05-02
JP5144499B2 (ja) 2013-02-13
DK2009101T3 (en) 2018-01-15
JPWO2007114325A1 (ja) 2009-08-20
EP4218801A2 (fr) 2023-08-02

Similar Documents

Publication Publication Date Title
CN105177091A (zh) 用于纯化双特异性抗体的抗体修饰方法
US20220267822A1 (en) Methods for producing polypeptides by regulating polypeptide association
CN101479381B (zh) 调控抗体血液动力学的方法
US20200087380A1 (en) Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
CN107002068B (zh) 诱导细胞毒性的治疗剂
CN101460622A (zh) 用于纯化双特异性抗体的抗体修饰方法
CN115028722A (zh) 抗tslp抗体及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1217217

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151223

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1217217

Country of ref document: HK